>>Signaling Pathways>> Membrane Transporter/Ion Channel>> Calcium Channel>>NP118809

NP118809

Catalog No.GC36766

NP118809는 IC50이 0.11μM인 강력한 N형 칼슘 채널 차단제입니다. 또한 IC50이 12.2μM인 L형 칼슘 채널을 덜 강력하게 억제합니다.

Products are for research use only. Not for human use. We do not sell to patients.

NP118809 Chemical Structure

Cas No.: 41332-24-5

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$76.00
재고 있음
100mg
US$69.00
재고 있음
200mg
US$87.00
재고 있음
500mg
US$108.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NP118809 is a potent N-type calcium channel blocker, with an IC50 of 0.11 μM; also less potently inhibits L-type calcium channel with an IC50 of 12.2 μM. N-Type Ca2+ Channel|0.11 μM (IC50)|L-type calcium channel|12.2 μM (IC50)

NP118809 is a potent N-type calcium channel blocker, with an IC50 of 0.11 μM; also inhibits L-type calcium channel with an IC50 of 12.2 μM. NP118809 inhibits the hERG potassium channel in HEK cells, with an IC50 of 7.4 μM[1].

NP118809 (25 mg/kg, i.p.) shows significant analgesic activity in the phase IIA portions of the rat formalin model[1]. NP118809 (30 mg/kg, p.o.) results in 80.3% inhibition of mechanical allodynia and 96.3% inhibition of thermal hyperalgesia in the rat spinal nerve ligation model[2].

[1]. Zamponi GW, et al. Scaffold-based design and synthesis of potent N-type calcium channel blockers. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6467-72. [2]. Pajouhesh H, et al. Structure-activity relationships of diphenylpiperazine N-type calcium channel inhibitors. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1378-83.

리뷰

Review for NP118809

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NP118809

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.